-transparent.png){kind=logo}
The periodontal condition of 40 adult epileptic subjects (mean age 51 years) receiving long-term therapy (mean 18 years) with phenytoin (PHT) or carbamazepine (CBZ) was studied. The subjects completed a questionnaire and underwent clinical and radiologic examination. Patients receiving PHT exhibited the same level of alveolar bone loss as those receiving CBZ. Patients receiving PHT exhibited more units with gingival overgrowth, reflected by the significantly higher number of gingival units with increased probing depth (p < 0.05). The results indicate that long-term PHT does not result in increased risk for alveolar bone loss as compared with CBZ.
Related Publications
G Dahllöf, and
H Preber, and
S Eliasson, and
H Rydén, and
J Karsten, and
T Modéer
October 1985,
Clinical endocrinology,
G Dahllöf, and
H Preber, and
S Eliasson, and
H Rydén, and
J Karsten, and
T Modéer
June 1990,
The Japanese journal of psychiatry and neurology,
G Dahllöf, and
H Preber, and
S Eliasson, and
H Rydén, and
J Karsten, and
T Modéer
January 1996,
Functional neurology,
G Dahllöf, and
H Preber, and
S Eliasson, and
H Rydén, and
J Karsten, and
T Modéer
December 1994,
International journal of immunopharmacology,
G Dahllöf, and
H Preber, and
S Eliasson, and
H Rydén, and
J Karsten, and
T Modéer
January 1981,
Human genetics,
G Dahllöf, and
H Preber, and
S Eliasson, and
H Rydén, and
J Karsten, and
T Modéer
January 1986,
Therapeutic drug monitoring,
G Dahllöf, and
H Preber, and
S Eliasson, and
H Rydén, and
J Karsten, and
T Modéer
August 1978,
Acta neurologica Scandinavica,
G Dahllöf, and
H Preber, and
S Eliasson, and
H Rydén, and
J Karsten, and
T Modéer
December 1980,
Zeitschrift fur arztliche Fortbildung,
G Dahllöf, and
H Preber, and
S Eliasson, and
H Rydén, and
J Karsten, and
T Modéer
January 1992,
Acta neurologica,
G Dahllöf, and
H Preber, and
S Eliasson, and
H Rydén, and
J Karsten, and
T Modéer
January 2006,
Chronobiology international,
